Rocket Pharmaceuticals (RCKT) Operating Leases (2019 - 2026)

Rocket Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $2.5 million in Q1 2026.

• Quarterly Operating Leases fell 19.45% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (down 19.45% YoY) and the FY2025 annual result came in at $2.6 million, down 20.2% from the prior year.
• Operating Leases retreated to $2.5 million in Q1 2026 per RCKT's latest filing, from $2.6 million in the prior quarter.
• Over five years, Operating Leases peaked at $3.7 million in Q1 2024 and troughed at $200000.0 in Q1 2023.
• A 5-year average of $2.4 million and a median of $2.9 million in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2024: Operating Leases sank 72.18% in 2023, then jumped 1757.0% in 2024.
• Over 5 years, Operating Leases stood at $1.1 million in 2022, then surged by 173.25% to $3.0 million in 2023, then advanced by 9.59% to $3.3 million in 2024, then dropped by 20.2% to $2.6 million in 2025, then retreated by 4.12% to $2.5 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $2.5 million, $2.6 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.